GammaDelta Therapeutics

11 articles about GammaDelta Therapeutics

• 

  Takeda Augments IO Portfolio with Third Build-to-Buy Acquisition in a Year

  1/10/2022

  The planned acquisition will give Takeda full access to Adaptate’s antibody-based γδ T cell engager platform, which includes both pre-clinical and discovery assets.
• 

  Takeda Snaps Up Partner GammaDelta to Bolster Oncology Pipeline

  10/27/2021

  The deal was struck one month after GammaDelta dosed its first patient in a Phase I acute myeloid leukemia (AML) trial.

• GammaDelta Therapeutics Initiates First-in-Human Phase 1 Trial of GDX012 for the Treatment of Acute Myeloid Leukaemia

  9/15/2021

  GammaDelta Therapeutics Ltd. today announced that it has initiated a first-in-human Phase I clinical trial evaluating GDX012 for the treatment of acute myeloid leukaemia (AML)

• GammaDelta Therapeutics Receives FDA Clearance of IND Application for GDX012, a Novel Allogeneic Variable Delta 1 Gamma-delta T Cell Cancer Therapy

  5/20/2021

  GammaDelta Therapeutics, a company focussed on exploiting the unique properties of gamma delta T cells for immunotherapy, announced the U.S. Food and Drug Administration has cleared the Investigational New Drug application for the Company’s allogeneic variable delta 1 gamma-delta T cell therapy, GDX012, to be investigated as a treatment for haematological malignancies.

• Adaptate Biotherapeutics formed to develop antibody-based therapies that modulate gamma delta T-cells

  10/16/2019

  GammaDelta Therapeutics spins-out new company to accelerate antibody-based assets towards clinical studies

• 

  GammaDelta Therapeutics Spins Out Adaptate Bio to Develop Gammadelta T-Cells

  10/16/2019

  Adaptate will build on GammaDelta’s expertise in modulating gammadelta T-cell activity using antibodies, with a focus on developing an immune response to cancer.

• GammaDelta Therapeutics announces Publication of New Data in Nature Immunology describing the Independent Immune Function of gamma delta (γδ) T cell receptors

  11/13/2018

  Findings support development of γδ T cells for gastrointestinal diseases

• Meet GammaDelta Therapeutics's CEO—The Scientist Who Helped GlaxoSmithKline Launch 7 Cancer Drugs

  6/13/2017

• What Takeda is Getting for Its Money in Its Latest $100 Million Deal With GammaDelta Therapeutics

  5/24/2017

• GammaDelta Therapeutics Expands Management Team Led By Paolo Paoletti As CEO

  5/3/2017

• GammaDelta Therapeutics Raises Seed Funding From Abingworth

  9/16/2016